12 May
2023
19:12 E.S.T.

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Read more

11 May
2023
08:37 E.S.T.

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Read more

04 May
2023
14:49 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Read more

02 May
2023
12:05 E.S.T.

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read more

27 Apr
2023
10:01 E.S.T.

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Read more

24 Apr
2023
11:39 E.S.T.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Read more

17 Apr
2023
02:00 E.S.T.

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Read more

11 Apr
2023
16:30 E.S.T.

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

Read more

04 Apr
2023
16:30 E.S.T.

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million

Read more

14 Mar
2023
17:00 E.S.T.

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

Read more